SOM Biotech announces a worldwide license with Corino Therapeutics for its SOM0226 compound against amyloidosis Blog Post

SOM Biotech, a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases today announces an exclusive worldwide license agreement with U.S. Corino Therapeutics for the clinical development and commercialization of SOM0226, a drug for the treatment of Transthyretin Amyloidosis (ATTR). License was executed after very promising results of the therapeutic agent discovered by SOM –based at the Barcelona Science Park– in a Phase 2a study.

 

Tomàs Marquès-Bonet awarded by the Howard Hughes Medical Institute Blog Post

Researcher Tomàs Marquès-Bonet, director of the Institute for Evolutionary Biology (IBE), and leader of the Comparative Genomics group at CNAG-CRG at the Barcelona Science Park, has been awarded the International Early Career Award by the Howard Hughes Medical Institute (HHMI, USA). He will receive $ 650,000 spread over five years, starting in September 2017. A total of 1,600 researchers from around the world attended the call, of which only 41 were selected. To date, only 5 investigators in Spain have received this recognition.

 

A cellular model to study the relation between neurodegenerative diseases is designed Blog Post

Thanks to the cells of a patient with a rare neurodegenerative disease -the Gerstmann-Sträussler-Scheinker syndrome (GSS)- researchers from the Institute for Bioengineering of Catalonia (IBEC), at the Barcelona Science Park, and the Institute of Neurosciences of the UB have created neurons showing other neurodegenerative processes which so far had not been related to this minority disease. This scientific finding could open new doors to the study of neurodegenerative pathologies with diagnoses similar to Parkinson’s or Alzheimer’s according to the study published in the journal Molecular Neurobiology.

 

Manuel Serrano expands his pioneering research into regenerative medicine at IRB Barcelona Blog Post

This morning, the scientist Manuel Serrano, the director of the Institute for Research in Biomedicine (IRB Barcelona) Joan J. Guinovart, the director of Research and Knowledge Section of the “la Caixa” Banking Foundation Jordi Portabella and the director of the Institució Catalana de Recerca i Estudis Avançats (ICREA) Antonio Huerta have presented the challenges in regenerative medicine that Serrano will tackle from his new Cellular Plasticity and Disease Lab at IRB Barcelona located at the Barcelona Science Park.

 

The Institute of Cosmos Sciences sets up a technology unit at the Barcelona Science Park Blog Post

The Institute of Cosmos Sciences of the UB (ICCUB) has set up a Technology Unit (ICCUB-Tech) at the Barcelona Science Park to develop highly specialized instrumentation and massive data analysis for scientific and technology projects, as well as for companies. With this initiative, the center – one of the four units that make up the Institute of Space Studies of Catalonia (IEEC)– wants to apply the expertise acquired in space science and particle physics projects to other fields, such as medicine, genomics and marine geociences.

 

Esteve y Farmamundi renew their collaboration agreement to provide humanitarian aid Blog Post

Esteve and Farmamundi have renewed their collaboration agreement once again, under which the laboratory participates as a member of the organization’s emergency fund and, at the same time, as a provider of medicines. The medical and pharmaceutical material donated by esteve in 2016 were distributed to hospitals, clinics, health centers, welcome centers for sick people, refugee camps, orphanages and nursing homes in 23 countries.

 

A study reveals the biological changes in breast cancer between the primary tumour and metastases Blog Post

Researchers at  the Institute for Research in Biomedicine (IRB Barcelona) and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and have described that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes. The work – published in Cancer Research– has also shown that between the initial tumour and the metastasis the subtype of breast cancer can change in up to 40% of cases.

 

Awards of the UB Board of Trustees and the FBG: Ten years fostering knowledge transfer Blog Post

The Awards of the Board of Trustees of the University of Barcelona (UB) and Bosch i Gimpera Foundation (FBG) –based at the Barcelona Science Park (PCB)– celebrate their tenth edition. These prizes are awarded in two categories: the Antoni Caparrós Prize for the best knowledge transfer project, and the Senén Vilaró Prize for the best innovative company which, since its creation in 2008, has recognized eight companies based at PCB: Meteosim, Biocontrol Technologies, Intelligent Pharma, Enantia, Neurotec Pharma, Infinitec Assets, Endor Technologies and Minoryx Therapeutics.